SI3334747T1 - Globinsko nabito filtriranje proteinov, ki vežejo antigen - Google Patents

Globinsko nabito filtriranje proteinov, ki vežejo antigen

Info

Publication number
SI3334747T1
SI3334747T1 SI201631774T SI201631774T SI3334747T1 SI 3334747 T1 SI3334747 T1 SI 3334747T1 SI 201631774 T SI201631774 T SI 201631774T SI 201631774 T SI201631774 T SI 201631774T SI 3334747 T1 SI3334747 T1 SI 3334747T1
Authority
SI
Slovenia
Prior art keywords
antigen
binding proteins
depth filtration
charged depth
charged
Prior art date
Application number
SI201631774T
Other languages
English (en)
Inventor
Hai Hoang
Rafael Gonzalez
Junfen Ma
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56802689&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3334747(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of SI3334747T1 publication Critical patent/SI3334747T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201631774T 2015-08-13 2016-08-12 Globinsko nabito filtriranje proteinov, ki vežejo antigen SI3334747T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204831P 2015-08-13 2015-08-13
PCT/US2016/046929 WO2017027861A1 (en) 2015-08-13 2016-08-12 Charged depth filtration of antigen-binding proteins
EP16757780.8A EP3334747B1 (en) 2015-08-13 2016-08-12 Charged depth filtration of antigen-binding proteins

Publications (1)

Publication Number Publication Date
SI3334747T1 true SI3334747T1 (sl) 2024-02-29

Family

ID=56802689

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631774T SI3334747T1 (sl) 2015-08-13 2016-08-12 Globinsko nabito filtriranje proteinov, ki vežejo antigen

Country Status (15)

Country Link
US (2) US11098079B2 (sl)
EP (2) EP3334747B1 (sl)
JP (1) JP6889149B2 (sl)
DK (1) DK3334747T3 (sl)
ES (1) ES2964640T3 (sl)
FI (1) FI3334747T3 (sl)
HR (1) HRP20231544T1 (sl)
HU (1) HUE064252T2 (sl)
LT (1) LT3334747T (sl)
MA (1) MA42613A (sl)
PL (1) PL3334747T3 (sl)
PT (1) PT3334747T (sl)
SG (1) SG10202101105XA (sl)
SI (1) SI3334747T1 (sl)
WO (1) WO2017027861A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
CN107973487B (zh) * 2017-11-14 2021-03-02 东华大学 一种染整废水层级处理工艺及装置
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
BR112022013888A2 (pt) * 2020-01-15 2022-09-13 Hoffmann La Roche Métodos para reduzir a quantidade de impurezas não agregadas relacionadas ao produto (napris), produzir uma solução tamponada de anticorpos monoclonais (mabs) e produzir um mab, uso de um filtro de profundidade sintético e solução tamponada de anticorpos monoclonais
CN111410688A (zh) * 2020-03-13 2020-07-14 苏州智享众创孵化管理有限公司 一种提高双特异性抗体纯度的分离纯化方法
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
IL158719A0 (en) 2001-05-11 2004-05-12 Amgen Inc Peptides and related molecules that bind to tall-1
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
DK1425389T3 (da) 2001-08-23 2012-01-30 Genmab As Interleukin-15-(IL-15)-specifikke humane antistoffer
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
WO2003039485A2 (en) 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CN101287484B (zh) 2002-12-20 2012-10-10 安姆根有限公司 抑制肌肉生长抑制素的结合剂
EP3178492A1 (en) 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
PT1694360E (pt) 2003-11-04 2010-12-13 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
CN1886426A (zh) 2003-11-07 2006-12-27 伊姆尼斯公司 结合白细胞介素－4受体的抗体
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
WO2007035283A1 (en) 2005-09-15 2007-03-29 Wyeth Protein floculation using salts
WO2008036899A2 (en) * 2006-09-22 2008-03-27 Amgen Inc. Methods for removing viral contaminants during protein purification
EP2089431A4 (en) 2006-10-19 2010-03-17 Tolerx Inc METHOD AND COMPOSITIONS FOR EFFICIENT REMOVAL OF PROTEIN A FROM BINDING MOLECULE PREPARATION
CN101932591B (zh) 2007-07-09 2018-02-16 健泰科生物技术公司 在多肽的重组生产期间防止二硫键还原
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
DE102008037678A1 (de) * 2008-08-14 2010-02-25 Sartorius Stedim Biotech Gmbh Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid
JP5808249B2 (ja) 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
CA2759370C (en) * 2009-04-30 2020-02-11 Peter Schotte Method for the production of domain antibodies
SI3037104T1 (sl) 2009-10-20 2020-10-30 Abbvie Inc. Izolacija in prečiščevanje protiteles anti-IL-13 z uporabo afinitetne kromatografije beljakovine A
EP2490780A4 (en) 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF MIXED MODE CHROMATOGRAPHY FOR CAPTURE AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
US20120006751A1 (en) * 2010-05-07 2012-01-12 Millipore Corporation Enhanced Clarification Media
BR112012030530A2 (pt) 2010-05-18 2022-12-20 Abbvie Inc Aparelho e processo para purificação de proteínas
US20120264920A1 (en) * 2010-10-11 2012-10-18 Abbott Laboratories Processes for purification of proteins
WO2012054679A1 (en) 2010-10-20 2012-04-26 Medimmune, Llc Methods for processing inclusion bodies
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
EP3722304A1 (en) 2011-07-08 2020-10-14 EMD Millipore Corporation Improved depth filters for disposable biotechnological processes
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
PL2739641T5 (pl) 2011-08-02 2022-09-05 Takeda Pharmaceutical Company Limited Układy i sposoby zwiększania wydajności białka z procesów wytwarzania technikami rekombinacji
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
PL2794635T3 (pl) 2011-12-22 2019-02-28 F.Hoffmann-La Roche Ag Membranowa chromatografia jonowymienna
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2013177115A2 (en) * 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
CA2894908C (en) 2012-12-20 2022-07-12 Medimmune, Llc Methods of producing immunoconjugates
KR20160012975A (ko) 2013-06-04 2016-02-03 에이전시 포 사이언스, 테크놀로지 앤드 리서치 단백질 정제 프로세스
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
GB201318840D0 (en) 2013-10-24 2013-12-11 Univ Leeds Method and device for protein preparation
WO2015070068A1 (en) * 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
JP2017507149A (ja) 2014-02-27 2017-03-16 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 抗体精製方法
WO2015142777A1 (en) 2014-03-17 2015-09-24 Regeneron Pharmaceuticals, Inc. Clarification of mammalian cell culture
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016106291A1 (en) 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins

Also Published As

Publication number Publication date
SG10202101105XA (en) 2021-03-30
HUE064252T2 (hu) 2024-02-28
US11098079B2 (en) 2021-08-24
WO2017027861A1 (en) 2017-02-16
EP3334747B1 (en) 2023-09-27
US20210363180A1 (en) 2021-11-25
JP6889149B2 (ja) 2021-06-18
MA42613A (fr) 2018-06-20
ES2964640T3 (es) 2024-04-08
EP3334747A1 (en) 2018-06-20
EP4209499A1 (en) 2023-07-12
FI3334747T3 (fi) 2023-11-30
US20180230180A1 (en) 2018-08-16
HRP20231544T1 (hr) 2024-03-15
PL3334747T3 (pl) 2024-04-02
PT3334747T (pt) 2023-12-12
LT3334747T (lt) 2023-12-27
DK3334747T3 (da) 2023-12-11
JP2018526357A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
IL285366A (en) Multi-specific antigen-binding proteins
HK1253235A1 (zh) 抗tigit抗原結合蛋白及其使用方法
IL263690A (en) Purification of multispecific antibodies
HK1231400A1 (zh) 蛋白質的選擇性還原
IL251125A0 (en) Methods for the separation of diastereoisomers of gemcitabine-phosphate
SG10202101105XA (en) Charged depth filtration of antigen-binding proteins
IL248697A0 (en) Methods for purifying antibodies
ZA201808524B (en) Methods of affecting separation
GB201904142D0 (en) Improved method of FT-IMS
IL272670A (en) Preparation of micro-electrodes
SG10202007893TA (en) Methods of immunotherapy
IL252712A0 (en) Method for protein production
IL248694B (en) Nanoencapsulation of antigen binding molecules
HK1223624A1 (zh) 替諾福韋的固體形式
GB201609314D0 (en) Methods of forming compounds
TWM533475U (en) Improved structure of filter
GB201508443D0 (en) Methods of identifying USP-binding compounds